• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Alcon Announces Results of 2025 Annual General Meeting

    5/6/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care
    Get the next $ALC alert in real time by email
    • Shareholders approve all agenda items presented
    • Deborah Di Sanzo elected as new member of the Board
    • 2024 Compensation Report and Report on Non-Financial Matters approved in advisory votes

    Alcon Inc. (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2025 Annual General Meeting ("AGM").

    A total of 332,704,408 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,308,176.32, were represented at today's AGM.

    Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who stood for re-election, namely Lynn Bleil, Arthur Cummings, David Endicott, Thomas Glanzmann, D. Keith Grossman, Scott Maw, Karen May, Ines Pöschel and Dieter Spälti, for a term of office of one year. Shareholders also elected Deborah Di Sanzo to the Board, effective as of September 1, 2025.

    In addition, shareholders re-elected Thomas Glanzmann, Karen May, Scott Maw and Ines Pöschel to form the Compensation Committee for a period of one year.

    Discharge was granted to the members of the Board of Directors and the members of the Executive Committee for the 2024 financial year.

    In two separate binding votes, shareholders approved the maximum aggregate amount of compensation of the Board of Directors for the next term of office ending at the 2026 Annual General Meeting, and the Executive Committee for 2026 financial year.

    Shareholders also accepted the 2024 Report on Non-Financial Matters and the 2024 Compensation Report in separate, non-binding, consultative votes.

    Alcon shareholders approved the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2024.

    Shareholders also approved that a gross dividend of CHF 0.28 per dividend-bearing share be declared, and that, after appropriation of the dividend, the remaining amount of available earnings be carried forward.

    PricewaterhouseCoopers SA, Geneva, was re-elected as statutory auditors for the 2025 financial year. Hartmann Dreyer Attorneys-at-Law was also re-elected as the independent representative for a term of one year extending until the 2026 AGM.

    About Alcon

    Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

    Connect with us on

    Facebook

    LinkedIn

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250506608677/en/

    Investor Relations

    Dan Cravens

    Allen Trang

    + 41 589 112 110 (Geneva)

    + 1 817 615 2789 (Fort Worth)

    [email protected]

    Media Relations

    Steven Smith

    + 41 589 112 111 (Geneva)

    + 1 817 615 2501 (Fort Worth)

    [email protected]

    Get the next $ALC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALC

    DatePrice TargetRatingAnalyst
    5/14/2025$102.00 → $99.00Buy
    BTIG Research
    3/28/2025$107.00 → $110.00Buy
    Needham
    3/25/2025Neutral → Buy
    BofA Securities
    1/24/2025$108.00 → $106.00Buy
    Needham
    1/10/2025Neutral → Buy
    Redburn Atlantic
    12/17/2024$103.00 → $108.00Buy
    Needham
    11/12/2024Buy
    Needham
    10/10/2024Sell → Neutral
    Redburn Atlantic
    More analyst ratings

    $ALC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research reiterated coverage on Alcon with a new price target

      BTIG Research reiterated coverage of Alcon with a rating of Buy and set a new price target of $99.00 from $102.00 previously

      5/14/25 11:06:26 AM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Needham reiterated coverage on Alcon with a new price target

      Needham reiterated coverage of Alcon with a rating of Buy and set a new price target of $110.00 from $107.00 previously

      3/28/25 7:39:07 AM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Alcon upgraded by BofA Securities

      BofA Securities upgraded Alcon from Neutral to Buy

      3/25/25 8:19:22 AM ET
      $ALC
      Ophthalmic Goods
      Health Care

    $ALC
    SEC Filings

    See more
    • SEC Form 6-K filed by Alcon Inc.

      6-K - ALCON INC (0001167379) (Filer)

      5/13/25 4:31:01 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • SEC Form 6-K filed by Alcon Inc.

      6-K - ALCON INC (0001167379) (Filer)

      4/4/25 8:36:59 AM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • SEC Form 20-F filed by Alcon Inc.

      20-F - ALCON INC (0001167379) (Filer)

      2/25/25 4:34:11 PM ET
      $ALC
      Ophthalmic Goods
      Health Care

    $ALC
    Financials

    Live finance-specific insights

    See more
    • Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS

      First-quarter 2025 sales of $2.5 billion, in line on a reported basis, or up 3% constant currency1 (cc), versus first-quarter 2024 First-quarter 2025 diluted EPS of $0.70; core diluted EPS2 of $0.73 Generated $384 million cash from operations and $278 million free cash flow3 Dividend of CHF 0.28 per share approved by shareholders at the Annual General Meeting on May 6, 2025 Launched rich pipeline of innovative products, including Voyager, Precision7 and Systane Pro PF in Q1 2025; Unity VCS and PanOptix Pro in May 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31

      5/13/25 4:30:00 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Alcon Announces Results of 2025 Annual General Meeting

      Shareholders approve all agenda items presented Deborah Di Sanzo elected as new member of the Board 2024 Compensation Report and Report on Non-Financial Matters approved in advisory votes Alcon Inc. (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2025 Annual General Meeting ("AGM"). A total of 332,704,408 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,308,176.32, were represented at today's AGM. Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who stood f

      5/6/25 4:30:00 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Alcon Publishes Agenda for 2025 Annual General Meeting

      Alcon welcomes its shareholders to its third in-person AGM Alcon Board of Directors proposes to elect Deborah Di Sanzo as a new Board member Proposed dividend of CHF 0.28 cash per share Alcon (SIX/NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 6, 2025. Alcon is pleased to welcome shareholders to its third in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of Directors proposes to the AGM to elect Deborah Di Sanzo as a new Board member. An innovative business leader with more than thirty years of experience in the f

      4/4/25 1:00:00 AM ET
      $ALC
      Ophthalmic Goods
      Health Care

    $ALC
    Leadership Updates

    Live Leadership Updates

    See more
    • Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

      Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

      5/30/24 4:00:00 AM ET
      $ALC
      $NARI
      $OCS
      $RXST
      Ophthalmic Goods
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations

    $ALC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Alcon Inc.

      SC 13G - ALCON INC (0001167379) (Subject)

      2/13/24 3:47:46 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

      SC 13G/A - ALCON INC (0001167379) (Subject)

      2/10/23 1:35:38 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

      SC 13G/A - ALCON INC (0001167379) (Subject)

      2/10/22 5:01:03 PM ET
      $ALC
      Ophthalmic Goods
      Health Care

    $ALC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS

      First-quarter 2025 sales of $2.5 billion, in line on a reported basis, or up 3% constant currency1 (cc), versus first-quarter 2024 First-quarter 2025 diluted EPS of $0.70; core diluted EPS2 of $0.73 Generated $384 million cash from operations and $278 million free cash flow3 Dividend of CHF 0.28 per share approved by shareholders at the Annual General Meeting on May 6, 2025 Launched rich pipeline of innovative products, including Voyager, Precision7 and Systane Pro PF in Q1 2025; Unity VCS and PanOptix Pro in May 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31

      5/13/25 4:30:00 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Alcon Announces Results of 2025 Annual General Meeting

      Shareholders approve all agenda items presented Deborah Di Sanzo elected as new member of the Board 2024 Compensation Report and Report on Non-Financial Matters approved in advisory votes Alcon Inc. (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2025 Annual General Meeting ("AGM"). A total of 332,704,408 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,308,176.32, were represented at today's AGM. Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who stood f

      5/6/25 4:30:00 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS

      First-to-market innovations enhance efficiency, including HYPERVIT 30K, the world's fastest vitrectomy probe executing 30,000 cuts per minute1-3 Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye, supporting excellent patient care4,*,† Inventory will begin shipping to Australia, Europe, Japan and the U.S. from May onwards Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of the UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS). The new, versatile platform offers two configurations, a combined console (VCS) as well as a standalone cataract system (CS).

      4/25/25 8:00:00 AM ET
      $ALC
      Ophthalmic Goods
      Health Care